Company Overview
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.
Why Investors Should Care
Revenue has grown at a 345.0% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $4.04M (+254.7% YoY); net profit $-161.00M.
- Trailing 12 Months Year-on-year growth — revenue +254.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 345.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 345.02% |
| 1 Year: | 254.70% |
Stock Price Performance
| 1 Year: | +181.88% |
| 6 Months: | +20.67% |
| 3 Months: | +39.00% |
| 1 Month: | -0.24% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)48.63 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 345.0% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CGON CG Oncology, Inc. R2KR3KPHARMA | 74.67 | -27.76 | $6.59B | 0.00% | -25.08% | -21.39% | 345.02% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 194.00K | 0 | 9.00K | 529.00K | 111.00K | 43.00K | 52.00K | 0 | 1.67M | 1.08M | 1.16M |
| Operating Income | -9.72M | -12.33M | -14.04M | -22.47M | -25.85M | -28.30M | -42.20M | -48.74M | -51.13M | -66.39M | -86.40M |
| Net Income | -8.67M | -11.61M | -11.77M | -16.93M | -18.90M | -20.41M | -34.45M | -41.43M | -43.81M | -60.20M | -79.06M |
| Diluted EPS | -3.22 | -3.93 | -4.00 | -0.36 | -0.28 | -0.30 | -0.45 | -0.54 | -0.57 | -0.71 | -0.90 |
| R&D Expense | 7.84M | 9.83M | 11.73M | 17.21M | 18.47M | 19.62M | 27.47M | 31.33M | 27.88M | 43.73M | 54.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 204.00K | 1.14M | 4.04M |
| Operating Income | -55.45M | -114.67M | -190.77M |
| Net Income | -48.61M | -88.04M | -161.00M |
| Diluted EPS | -15.65 | -1.41 | -2.08 |
| R&D Expense | 45.75M | 82.10M | 116.64M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 147.75M | 199.30M | 754.80M | 791.59M |
| Current Assets | - | 147.21M | 194.12M | 754.21M | 759.48M |
| Cash & Equivalents | - | 88.14M | 8.27M | 257.07M | 32.49M |
| Inventory | - | - | - | 0 | 1.56M |
| Receivables | - | - | - | 0 | 688.00K |
| Total Liabilities | - | 22.57M | 14.51M | 21.42M | 38.99M |
| Current Liabilities | - | 15.43M | 14.25M | 21.37M | 30.84M |
| Long Term Debt | 12.06M | 6.53M | - | - | 3.00M |
| Total Debt | - | 15.94M | 461.00K | 238.00K | 7.02M |
| Total Equity | - | 125.18M | 184.79M | 733.38M | 752.60M |
| Shares Outstanding | - | 63.48M | 63.48M | 76.15M | 80.69M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -45.68M | -78.71M | -132.35M |
| Investing Cash Flow | -121.19M | -300.76M | -245.82M |
| Financing Cash Flow | 87.00M | 628.28M | 153.59M |
| Capital Expenditure | - | -234.00K | -134.00K |
| Free Cash Flow | - | -78.95M | -132.48M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | -27,180.9% | -10,067.3% | -4,722.1% |
| Net Margin % | -23,827.0% | -7,729.5% | -3,985.0% |
| ROE % | -26.3% | -12.0% | -21.4% |
| ROCE % | -30.0% | -15.6% | -25.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RTW Investments LP | 9.61% | 8.51M | $632.97M |
| 2 | T. Rowe Price Investment Management, Inc. | 7.46% | 6.62M | $491.90M |
| 3 | Decheng Capital LLC | 7.19% | 6.37M | $473.67M |
| 4 | Blackrock Inc. | 7.06% | 6.26M | $465.09M |
| 5 | Wellington Management Group, LLP | 6.01% | 5.32M | $395.84M |
| 6 | FMR, LLC | 4.69% | 4.16M | $309.37M |
| 7 | Price (T.Rowe) Associates Inc | 4.29% | 3.81M | $282.86M |
| 8 | TCG Crossover Management, LLC | 4.14% | 3.67M | $272.84M |
| 9 | Vanguard Portfolio Management LLC | 3.91% | 3.47M | $257.60M |
| 10 | State Street Corporation | 3.88% | 3.44M | $255.55M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CGON
CG Oncology (CGON) Stock Looks Fully Priced After A 160% Run - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOOVYyNl9wS09RR0YwcHpUcFowTVExdFJFdklpaHBvTVI3ejBDZHgtU1g0NGJKWURCVHNfM2V5dFZNTFY4YVVUX3NBeXpUTGxZU0FoNENOWllyYXVvZzNKQzF2SUJlTUtLMnRvU3UtaVBTTmJrRzlranNDMnZPZXUwRERLSEFOS2tfMzV3LW…
CG Oncology (CGON) officer to sell 29,630 shares after prior 100K trades - Stock Titan
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQRURUXy1pM3JNc2J3NmhkQjBIdE9Ba1NrQVFtOW45MVllX0pxUzJYVXUzYXRxS0Q5OXVTaF91Q3ZWVmtJLXZ4ZE5oWU9YanFWOXkweExnS2dRZEhCeEFOaHJna0ZhTUhvQWsxa2hOTUJ1M1ZHcWh2NTc0OFh3TUYtQ2ZiNkRkTjB1cWJ4ei…
Why (CGON) Price Action Is Critical for Tactical Trading - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxPOVR5RUQyRUdaeG1HUzJ5RFRTYWM2OThHTnVNNmoxNGVpNy1ha2pYTWNqQ215MWx4cUxxTjBWRU5RbzM0TjFiUHB5a1BJZlZwMGVoRlZiLWtBRklub1lnckQyc3BMYjhubW92THE2d24tRzAyeHB2NGxkeVU0Q2pkSlc1ZGJVeHNiYkptbl…
CG Oncology: Priced To Perfection On Future Pipeline Success - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxON08xS1RRSzFlQzZNVy1PaWxhTTNmRUNoQmZVdUc2VEViYWQ5NWREbndreUNRTGFGOURwUmJhbS1mRjI2cHlwUWdsYnoxS1FhNXdzRERON0RXQVZKbWtCQUVWV2p0MmlzSWRuT0x3cGQ5VURfUlVESWxkTXcwRWFzUFFtWmhHd0hUaGpzbT…
CG Oncology Stock (CGON) Opinions on Director's Massive Share Purchase | CGON Stock News - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQV3FLU3lXRkN4Vy1JcFZVdXNaTmVZLVBpZVdrOS1JV3Fub1hmem00bkJ5bjlsZHd4SDliNXY2SnRmd1lOT3BZajBrdEZqY2NvWTBSdEF0RWNWbngxT2E2Rjh3QU5wZDY3Qm10RVpnMVlmalVfVVM1ZmFRLVRpQnNEc3NOQzBrRUtfbk9XTz…
Morgan Stanley and Cantor Fitzgerald conferences will include talks by CG Oncology’s CEO in New York. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNdnRfMzZXUEhGdEF5TUt6bzlRZG9ab0R2SEtaTVZnMmFhNEFVbTQxbHVGdjFMWTRnd2pkYV9VaUVhSFQzTjFFN05PSFVzeVpkYVJWZ3RPRTU3SWIzbVZvWTlsc290WDQ1V1dBa1ZaSS1QU3gxcnpRTFdjeHhiTDU2NExISFFGWHN2T0xDa3…
CGON — Frequently Asked Questions
What is the current share price of CG Oncology, Inc. (CGON)?
As of 2026-09-07 16:24 PDT, CG Oncology, Inc. (CGON) trades at $74.67 on NasdaqGS. Its 52-week range is $25.42 to $80.68.
What is the market capitalisation of CGON?
CG Oncology, Inc. (CGON) has a market capitalisation of $6.59B on NasdaqGS.
What is the P/E ratio of CGON?
CGON trades at a trailing price-to-earnings (P/E) ratio of -27.76. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 8.05.
What is the return on equity (ROE) of CGON?
CGON has a return on equity (ROE) of -21.39%. Its return on capital employed (ROCE) is -25.08%.
Is CGON a good stock to buy?
This page provides a data-driven analysis of CG Oncology, Inc. (CGON), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.